Custom service
Anti-idiotype Antibody Production
Reagents that recognise the paratope, not the antigen.
An anti-idiotype antibody binds the variable region of another antibody. Depending on where it lands, it either recognises framework determinants shared across a family — the α type — or the antigen-combining site itself, the β type. The second is the one that matters commercially: it can act as a surrogate antigen, a pharmacokinetic capture reagent, or a positive control for anti-drug antibody assays.
Generating one is not a standard immunisation. The immunogen is the target antibody itself, or its Fab/F(ab')2 fragment to focus the response on the variable region and suppress constant-domain epitopes. Because the injected antibody is itself immunogenic in a foreign species, the campaign is run in mice or rabbits, and each fusion is screened against the intact target, against its Fab, and against an isotype-matched irrelevant antibody. Only wells that bind the Fab and not the isotype control are carried forward.
Specificity is the whole product. An anti-idiotype that also binds the framework of every human IgG1 is not an anti-idiotype, it is an anti-human IgG. Screening therefore includes panels of isotype-matched antibodies and, where available, the same antibody after antigen saturation — a true paratope-specific clone loses binding when the antigen occupies the site.
Service Highlights
Where it fits
Anti-idiotypes are essential in three places: pharmacokinetic assays that must measure free drug without interference from the target, immunogenicity assays that need a positive control with a defined paratope, and vaccine work where a β-type anti-idiotype serves as a surrogate for a polysaccharide or a small hapten that cannot be coated on a plate.
The approach is less useful when the target antibody is polyclonal or when its paratope is unknown and unstable. It is also a poor economic choice for a single assay run — the campaign costs more than the assay will ever return.
Documentation and QC
Each clone is delivered with a binding matrix against the target, its Fab, an isotype control and an unrelated antibody, plus competition data establishing α or β behaviour. Affinity to the Fab is measured by BLI, and any cross-reactivity to pooled human or mouse IgG is quantified and reported.
Frequently asked questions
What is the difference between Ab2α and Ab2β?
α-type anti-idiotypes bind framework determinants outside the combining site; β-type bind within or adjacent to the paratope and can mimic the antigen. Only β-type antibodies block antigen binding, which is why the classification is tested rather than assumed.
Can you make an anti-idiotype against a humanised antibody?
Yes, and the humanised framework reduces the number of foreign epitopes, which tends to focus the response on the CDRs. A Fab immunogen further improves the ratio of paratope-specific clones.
How specific is specific enough?
For PK assays we aim for no detectable binding to pooled IgG at 10 µg/mL and a signal-to-noise above 20 against the target Fab. The acceptance criteria are agreed before screening starts.
Send the target antibody and describe the assay it will sit in. Paratope specificity is a screening question, and we will tell you whether your target is likely to yield a β-type clone before the campaign begins.
Service Highlights
- Fab immunogen. Papain-derived Fab or F(ab')2 as immunogen, with constant-domain epitopes masked by tolerisation or removed by screening.
- Competitive epitope screening. Clones are tested with and without saturating antigen; paratope-specific binders drop out, framework binders do not.
- Subtype classification. Α versus β behaviour is documented by competition ELISA and by BLI epitope binning against the antigen.
- Species and isotype matching. Anti-mouse, anti-human, anti-rabbit and anti-VHH reagents in the detection species you need.
- Surrogate antigen use. Β-type anti-idiotypes are validated for the ability to block antigen binding, which is the property that makes them useful as assay calibrators.
- Conjugation-ready. Supplied unlabelled or pre-conjugated to HRP, biotin or magnetic beads for immediate assay use.
How the work runs
Target antibody qualification
Purity, aggregation and antigen-binding activity of the immunogen are confirmed. Aggregated IgG produces a response dominated by constant-region epitopes.
Fragment preparation
Fab or F(ab')2 is generated enzymatically and purified by SEC, with intact IgG removal confirmed by SDS-PAGE.
Immunisation and tolerance
Mice are immunised with the fragment; where the target is a mouse antibody, a rat or rabbit host is used to avoid self-tolerance.
Differential screening
Supernatants are screened against Fab, intact target, isotype control and an unrelated Fab. Ratio-based selection identifies paratope-directed clones.
Competition validation
Antigen competition ELISA and BLI binning establish whether the clone is α or β type, and whether it blocks antigen binding.
Subcloning and production
Two rounds of limiting dilution, isotyping, then scale-up to the required milligram quantity with conjugation if requested.
Specifications & timeline
- Timeline
- 12–16 weeks — to validated anti-ID
- Types
- Ab2α / Ab2β — framework vs paratope-specific
- Formats
- Fab, F(ab')2, IgG — species-matched options
- Timeline
- 12–16 weeks including screening and validation
- Immunogen
- Intact IgG, Fab or F(ab')2; 200–500 µg per campaign
- Screening panel
- Target Fab, intact target, isotype control, unrelated Fab, antigen-saturated target
- Host species
- Mouse, rat, rabbit; matched to the species of the target antibody
- Deliverables
- 2–4 cloned anti-idiotypes, α/β classification, competition data, 1–10 mg purified IgG
- Formats
- IgG, Fab, F(ab')2, biotin or HRP conjugate
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.